There is currently a widening gap between the tidal wave of gene discovery in neuropsychiatric conditions and our poor understanding of rare genomic variants' effects on cognitive, behavioral, and neuroimaging traits. Deleterious Single Nucleotide Variants (SNVs) and Copy Number Variants (CNVs) are identified in 5 to 40% of individuals with neuropsychiatric disorders. Still, little is known on how they confer risk to these conditions.
The lab is focussed on the growing need for large-scale, systematic, structured, and quantitative phenotypic and genomic research in rare genomic variants.
We work with data collected by our group as well as collaborators, in individuals who carry specific high-risk factors for psychiatric conditions such as the 16p11.2, 1q21.1, 15q13.3.
We also investigate genome-wide, the effects of rare recurrent and non-recurrent CNVs and SNVs on cognition and brain architecture.
Neuropsychiatric mutations delineate functional brain connectivity dimensions contributing to autism and schizophrenia
16p11.2 and 22q11.2 Copy Number Variants may represent mechanistic building blocks shared across idiopathic conditions.
Autism risk conferred by duplications is less influenced by IQ compared to deletions. CNVs increase autism risk similarly in individuals with high and low IQ.
Developmental trajectories of neuroanatomical alterations associated with the 16p11.2 Copy Number Variations
All large effect-size voxel-based differences are present at 4.5 years and seem to remain stable until the age of 23.
We are investigating the effects of CNVs on neuroanatomical traits such a cortical surface and thickness as well as resting-state fMRI. We are analyzing data from large international cohorts as well as neuroimaging data collected by our lab on individuals who carry rare genomic variants. Our goal is to understand how genomic variants that affect specific biological processes modulate brain architecture.
We are using rare variants to map the effects of biological processes on cognition, behavior, and risk for psychiatric conditions. We developed MIND·CNV - which is a online tool created to help clinicians and researchers estimate the effect size of CNVs on cognitive ability and risk for autism.
We are assessing the efficacy of metformin in individuals with Fragile X Syndrome.
In particular, effects on language and behavioral outcomes.
Clinical trial link
The Transforming Autism Care Consortium (TACC) is a research network that connects and mobilizes Quebec’s strengths in autism research. Our main project is the Quebec 1000 families cohort (Q1k) gathering cognitive, behavioral, eye tracking, EEG, and neuroimaging data on 1000 families.
Sebastien JacquemontLab director - Geneticist
Guillaume HuguetResearch associate
Charles-Olivier MartinBrain Canada manager
Laura PeyrasLab manager
Marylin KoayesGenetic counselor
Clara MoreauPostdoc - Neuroimaging
This tool was created to help clinicians estimate the potential impact of deletions in the genome (hg19 genomic map) on cognition based on the results of Huguet et al. (JAMA psychiatry 2018).Try out our tools!